Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

Clinical trial NCT05296525 · TERMINATED

Trial details

NCT number: NCT05296525
Sponsor: Gamida Cell ltd
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-Hodgkin Lymphoma

Start date: 2022-07-05
Primary completion: 2024-04-22
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.